In Silico Genesis presented our Alzheimer’s strategy to the One Nucleus CNS Leadership Seminar Series held in London, on the 11th of Feb. 2013.
This seminar will look at:
• The Prime Minister’s Dementia Challenge
• Pharmacotherapy for Alzheimer’s disease – progress and prospects
• The emerging scientific advances that may enable greater success in the future
10.30 – Registration
11.00 – Welcome from the Chair
Janet Knowles, Partner, Eversheds
11.10 – The Prime Minister’s Dementia Challenge
Mark Treherne, CEO, Life Sciences Investment Organisation, UKTI
11.30 – What are the prospects of slowing the progression of Alzheimer’s disease?
Prof Alan Palmer, Director MS Therapeutics
12.00 – What insights do biomarkers provide into the recent Phase III failures?
Andrea Les, Senior Imaging Scientist, IXICO
12.20 – Q&A with the speakers
12.45 – Networking Lunch
13.45 – Introduction from the Chair
13.45 Is there a future for the amyloid theory in treating Alzheimer’s disease?
Eric Karran, Alzheimer’s Research UK
14.05 Targeting Tau hyperphosporylation in AD
Ian Pike, COO, Proteome Sciences
14.25 – Genetic basis of Alzheimer disease susceptibility
Prof. Julie Williams, Cardiff University School of Medicine
14.45 – FGL Peptides as neuroprotectives in AD
Steve Rees, COO, ENKAM Pharmaceuticals A/S
15.05 – Translational genomic medicine and companion diagnostic development
Kimberley Treherne (then, Williams), In Silico Genesis
15.25 – Closing Remarks from one Nucleus
Tony Jones, Director of Business Development, One Nucleus
15.30 – Networking drinks
16.30 – Close
Shown above can be found at http://onenucleus.com/onenucleus-events?id=692.